Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Benmebarek MR, Cadilha BL, Herrmann M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger C, Brauchle B, Rohrbacher L, Oner A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein C, Subklewe M, Endres S, Hopfner KP, Kobold S. Benmebarek MR, et al. Among authors: schmitt s. Leukemia. 2021 Aug;35(8):2243-2257. doi: 10.1038/s41375-020-01109-w. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414484 Free PMC article.
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S, Vick B, Hiller B, Schmitt S, Marcinek A, Perini ED, Leutbecher A, Augsberger C, Reischer A, Tast B, Humpe A, Jeremias I, Subklewe M, Fenn NC, Hopfner KP. Tahk S, et al. Among authors: schmitt s. J Hematol Oncol. 2021 Sep 27;14(1):155. doi: 10.1186/s13045-021-01163-6. J Hematol Oncol. 2021. PMID: 34579739 Free PMC article.
Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells.
Schmitt S, Tahk S, Lohner A, Hänel G, Maiser A, Hauke M, Patel L, Rothe M, Josenhans C, Leonhardt H, Griffioen M, Deiser K, Fenn NC, Hopfner KP, Subklewe M. Schmitt S, et al. Front Immunol. 2020 Nov 12;11:602802. doi: 10.3389/fimmu.2020.602802. eCollection 2020. Front Immunol. 2020. PMID: 33281829 Free PMC article.
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.
Roas M, Vick B, Kasper MA, Able M, Polzer H, Gerlach M, Kremmer E, Hecker JS, Schmitt S, Stengl A, Waller V, Hohmann N, Festini M, Ludwig A, Rohrbacher L, Herold T, Subklewe M, Götze KS, Hackenberger CPR, Schumacher D, Helma-Smets J, Jeremias I, Leonhardt H, Spiekermann K. Roas M, et al. Among authors: schmitt s. Blood. 2023 Mar 2;141(9):1023-1035. doi: 10.1182/blood.2021015246. Blood. 2023. PMID: 35981498 Free article.
The Obstacle is the Way: Finding a Path to Hepatitis C Elimination.
Lo Re V 3rd, Price JC, Schmitt S, Terrault N, Bhattacharya D, Arohnson A. Lo Re V 3rd, et al. Among authors: schmitt s. Clin Infect Dis. 2024 May 16:ciae231. doi: 10.1093/cid/ciae231. Online ahead of print. Clin Infect Dis. 2024. PMID: 38752395 No abstract available.
The obstacle is the way: Finding a path to hepatitis C elimination.
Lo Re V 3rd, Price JC, Schmitt S, Terrault N, Bhattacharya D, Aronsohn A. Lo Re V 3rd, et al. Among authors: schmitt s. Hepatology. 2024 May 16. doi: 10.1097/HEP.0000000000000807. Online ahead of print. Hepatology. 2024. PMID: 38752360 No abstract available.
1,218 results